US74366E1029
US74366E1029
Protagonist Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 9.3B EUR | 7.93B EUR | 6.77B EUR | 5.47B EUR |
Enterprise Value | 8.28B EUR | 7.52B EUR | 6.59B EUR | 5.35B EUR |
Valuation Multiples | ||||
Trailing P/E | 139.54x | 95.62x | -- | -- |
Forward P/E | -721.72x | -- | -- | -- |
Price to Sales | 32.98x | 28.11x | 91.4x | 308.88x |
Price to Book | 11.05x | 9.42x | 10.33x | 8.89x |
EV/Revenue | 29.36x | 26.66x | 88.92x | 302.2x |
EV/EBITDA | 138.27x | 125.52x | -- | -- |
Price to FCF (P/FCF) | 96.73x | 60.71x | -- | -- |
EV/FCF | 86.12x | 57.56x | -- | -- |
FCF Yield | 1.03% | 1.65% | -1.74% | -1.26% |